Posted by Michael Wonder on 12 Sep 2020
NICE widens its Zolgensma appraisal due to European Marketing Authorisation
11 September 2020 - England’s NICE is expanding its appraisal of Zolgensma, a gene therapy for spinal muscular atrophy, according to a press release from SMA UK.
NICE had previously planned to conduct evaluations of clinical trial and cost effectiveness data, with the end goal of determining whether the treatment should be covered by the NHS, the U.K.’s public health care system.
Now, the Appraisal Committee has expanded its planned Zolgensma appraisal to be more in line with the therapy’s recent European marketing authorisation.
